Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688253'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.22 Med: 15.75 Max: 293.29
Current: 230.26
During the past 8 years, the highest EV-to-FCF of Innovita Biological Technology Co was 293.29. The lowest was 6.22. And the median was 15.75.
SHSE:688253's EV-to-FCF is ranked worse than 94.91% of 334
companies
in the Biotechnology industry
Industry Median: 15.69
vs SHSE:688253: 230.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Innovita Biological Technology Co (SHSE:688253) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Innovita Biological Technology Co's PE Ratio (TTM) for today is calculated as:
Innovita Biological Technology Co's share price for today is ¥54.13.
Innovita Biological Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Innovita Biological Technology Co EV-to-FCF Related Terms
Innovita Biological Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688253 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Innovita Biological Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovita Biological Technology Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Innovita Biological Technology Co's EV-to-FCF falls into.
Innovita Biological Technology Co's current Enterprise Value is ¥5,485.5 Mil.
Innovita Biological Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥23.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co (SHSE:688253) has a EV-to-FCF of 230.26 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Innovita Biological Technology Co and its competitors. This is 1362% above median its historical median of 15.75. Over the past decade, Innovita Biological Technology Co's EV-to-FCF has ranged from 6.22 to 293.29. According to the industry distribution chart, Innovita Biological Technology Co ranks #317 out of 334 companies in the Biotechnology industry, placing it in the top 94.9%.
Is Innovita Biological Technology Co's EV-to-FCF too high?
Innovita Biological Technology Co's current EV-to-FCF of 230.26 is 1362% above median its 10-year median of 15.75. Over the past 10 years, this metric has ranged from a low of 6.22 to a high of 293.29. The Biotechnology industry median EV-to-FCF is 15.69. Innovita Biological Technology Co's value of 230.26 is 1367.6% above this industry median. Based on the distribution chart, Innovita Biological Technology Co ranks #317 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovita Biological Technology Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innovita Biological Technology Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovita Biological Technology Co ranks #317 out of 334 companies for EV-to-FCF. This places Innovita Biological Technology Co in the lower half of its industry. The industry median EV-to-FCF is 15.69. Innovita Biological Technology Co's value of 230.26 is 1367.6% above this benchmark. Historically, Innovita Biological Technology Co's own EV-to-FCF has ranged from 6.22 to 293.29 over the past decade. While the company's 10-year median is 15.75 vs. the industry median of 15.69, Innovita Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.69, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovita Biological Technology Co's current EV-to-FCF of 230.26 is 1367.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Innovita Biological Technology Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovita Biological Technology Co's current EV-to-FCF is 230.26, which is 1362% above median its own 10-year median of 15.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovita Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Innovita Biological Technology Co (SHSE:688253) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥20.48, compared to a current price of ¥54.13 — trading 164.3% above its estimated fair value. The current EV-to-FCF is 230.26, which is 1362% above median its 10-year median of 15.75 and 1367.6% above the Biotechnology industry median of 15.69. Innovita Biological Technology Co's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Innovita Biological Technology Co (SHSE:688253), the current EV-to-FCF is 230.26 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovita Biological Technology Co (SHSE:688253) Overvalued in 2026?
Based on GuruFocus' analysis, Innovita Biological Technology Co stock appears to be overvalued.
The current stock price of ¥54.13 is trading 164.3% above its estimated GF Value™ of ¥20.48.
GuruFocus considers Innovita Biological Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688253:
EV-to-FCF: 230.26 (1362% above median its 10-year median of 15.75)
GF Value™: ¥20.48 vs. price of ¥54.13 (164.3% above fair value)
Industry Position: 1367.6% above the Biotechnology median (#317 of 334)
No single metric tells the full story. See the SHSE:688253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovita Biological Technology Co Business Description
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
61GF Score
Get the complete analysis for SHSE:688253
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688253 has been successfully added to your 
